3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
7
Genitourinary
3
Sarcoma
2
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Sarcoma, Synovial
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
pembrolizumab
120
Carboplatin
114
Pemetrexed
74
Cisplatin
71
Nivolumab
68
Paclitaxel
58
Docetaxel
56
Radiotherapy
41
Erlotinib Hydrochloride
41
Gemcitabine
35
Etoposide
34
atezolizumab
30
osimertinib
29
Cetuximab
27
Ipilimumab
25
Bevacizumab
25
Radiosurgery
22
durvalumab
21
Cyclophosphamide
20
Drug Therapy
18
130-nm albumin-bound paclitaxel
17
avelumab
14
Taxes
14
Gefitinib
14
Albumin-Bound Paclitaxel
14
Irinotecan
13
Injections
13
fludarabine
11
Radiation
11
cemiplimab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
tazemetostat
×
Thoracic
×
Clear all
NCT02875548
2025-11-04
TRuST
Ipsen
Phase 1/2
Completed
58 enrolled